natgillin/translations-raw huggingface dataset:
TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including GuillainBarré syndrome. 
Antagonisti TNF, z zdravilom Humira vred, so bili v redkih primerih povezani s pojavom ali poslabšanjem kliničnih simptomov in/ali rentgenoloških znakov demielinizirajoče bolezni osrednjega živčnega sistema, vključno z multiplo sklerozo in optičnim nevritisom, in periferne demielinizirajoče bolezni, vključno z Guillain-Barréjevim sindromom.
Look at the expiry date on the syringe. 
• Preverite datum izteka roka uporabnosti na brizgi.
The white needle sleeve will cover the needle tip. 
Bel tulec bo prekril konico igle.
Among patients with baseline HS-related skin pain assessment ≥ 3, based on Numeric Rating Scale 0 - 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine. 
b Med bolniki z izhodiščnim rezultatom 3 ali več pri ocenjevanju bolečine, povezane s hidradenitis suppurativa, po numerični ocenjevalni lestvici od 0 do 10; 0 = brez bolečin na koži, 10 = najhujša možna bolečina na koži.
The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of pivotal studies was 5.9% for patients taking Humira and 5.4% for control treated patients. 
Delež bolnikov, ki so zaradi neželenih učinkov prekinili zdravljenje med dvojno slepim, kontroliranim delom študij, ki podpirajo vlogo za pridobitev dovoljenja za promet, je bil 5,9 % v skupini, ki je prejemala zdravilo Humira, in 5,4 % v kontrolni skupini.
Tell your doctor immediately if you notice any of the following 
Svojemu zdravniku takoj povejte, če opazite kaj od naslednjega
The pre-filled pen is now ready to use. 
Napolnjeni injekcijski peresnik je zdaj pripravljen za uporabo.
If you stop using Humira 
Če ste prenehali uporabljati zdravilo Humira
Enthesitis-related arthritis is an inflammatory disease of the joints and the places where tendons join the bone. 
Artritis, povezan z entezitisom je vnetna bolezen sklepov in in mest, kjer se tetive prirastejo na kost.
• On rare occasions, treatment with Humira could result in lupus-like syndrome. 
• V redkih primerih lahko zdravljenje z zdravilom Humira povzroči lupusu podoben sindrom.
Health-related quality of life and physical function were assessed using the disability index of the Health Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a pre-specified primary endpoint at Week 52 in RA study III. 
Z zdravjem povezano kakovost življenja in telesno funkcijo so v štirih originalnih ustreznih in dobro kontroliranih študijah ocenjevali z indeksom invalidnosti z vprašalnikom HAQ (Health Assessment Questionnaire), ki je bila v študiji revmatoidnega artritisa III vnaprej določena primarna končna točka po 52 tednih.
In patients with moderate to severe hidradenitis suppurativa, anti-adalimumab antibodies were identified in 10/99 subjects (10.1%) treated with adalimumab. 
Pri bolnikih z zmerno do hudo obliko hidradenitis suppurativa so bila protitelesa proti adalimumabu odkrita pri 10/99 oseb (10,1 %), ki so bile zdravljene z adalimumabom.
The needle will then be covered by the automatic needle guard. 
Avtomatski ščitnik za iglo bo nato pokril iglo.
• Do not remove the needle cover while allowing Humira to reach room temperature 
• Pokrovčka igle ne odstranite dokler zdravilo Humira ne doseže sobne temperature.
Mark your calendar with the stickers provided to remind you of the date for your next dose. 
S priloženimi nalepkami si na koledarju označite datum, ko morate vzeti naslednji odmerek.
Of the 424 subjects included in the uncontrolled long-term extension of Studies UV I and UV II, 60 subjects were regarded ineligible (e.g. due to deviations or due to complications secondary to diabetic retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis of efficacy. 
Od 424 bolnikov, ki so bili vključeni v nekontrolirani dolgoročni podaljšek študij UV I in UV II, je bilo 60 bolnikov neprimernih (npr. zaradi odstopanj ali zapletov, sekundarno ob diabetični retinopatiji zaradi kirurškega posega sive mrene ali vitrektomije) in so bili izključeni iz primarne analize učinkovitosti.
The rate of pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%) in the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32 (9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16). 
Razmerje nosečnosti, ki so se končale vsaj z enim živorojenim otrokom z večjim defektom ob rojstvu, je bilo 6/69 (8,7 %) pri nosečnicah, zdravljenih z adalimumabom z RA, in 5/74 (6,8 %) pri nezdravljenih nosečnicah z RA (neprilagojeno razmerje obetov 1.31, 95 % interval zaupanja 0.38-4.52), ter 16/152 (10,5 %) pri nosečnicah, zdravljenih z adalimumabom s CB, in 3/32 (9,4 %) pri nezdravljenih nosečnicah s CB (neprilagojeno razmerje obetov 1.14, 95 % interval zaupanja 0.31-4.16).
Neurologic evaluation should be performed in patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly during treatment to assess for pre-existing or developing central demyelinating disorders. 
Pri bolnikih z neinfekcijskim intermediarnim uveitisom je treba pred začetkom zdravljenja z zdravilom Humira in redno med zdravljenjem opravljati nevrološko oceno, da se oceni že obstoječe ali razvijajoče se demielinizirajoče bolezni osrednjega živčevja.
• Hold the pre-filled syringe at eye level with one hand so you can see the air in the pre-filled syringe 
• Napolnjeno injekcijsko brizgo z eno roko držite v višini oči, tako da lahko vidite zrak v napolnjeni injekcijski brizgi
• worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness) 
• poslabšanje stanja, ki se imenuje dermatomiozitis (viden kot kožni izpuščaj, ki ga spremlja mišična šibkost)
Patients taking TNF -antagonists are more susceptible to serious infections. 
Bolniki, ki uporabljajo antagoniste tumor nekrotizirajočega faktorja (TNF), so bolj dovzetni za resne okužbe.
• With the other hand, hold syringe at 45-degree angle to skin, with the grooved side up. 
• Z drugo roko držite brizgo pod kotom 45 stopinj na kožo, z užlebljenim delom obrnjenim navzgor.
Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after Humira administration. 
Po uporabi zdravilaHumira se je zmanjšala tudi serumska raven matriksnih metaloproteinaz (MMP-1 in MMP-3), ki povzročajo remodeliranje tkiva, odgovorno za uničenje hrustanca.
Psoriasis Study IV compared efficacy and safety of Humira versus placebo in 217 adult patients with moderate to severe nail psoriasis. 
Študija pri psoriazi IV je primerjala učinkovitost in varnost zdravila Humira v primerjavi s placebom pri 217 odraslih bolnikih z zmerno do hudo psoriazo nohtov.
The Humira pre-filled pen is available in packs containing 1, 2, 4 and 6 pre-filled pens. 
Napolnjeni injekcijski peresnik zdravila Humira je na voljo v pakiranjih, ki vsebujejo 1, 2, 4 ali 6 napolnjenih injekcijskih peresnikov.
Of the patients who lost adequate response after re-randomisation to placebo who then enrolled into the open-label extension trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, respectively. 
Med bolniki, ki so izgubili ustrezen odziv ob ponovni randomizaciji na placebo med podaljšanim odprtim preskušanjem, je po 12 tednih ponovne terapije PASI 75 znova doseglo 38 % (25/66), po 24 tednih pa 55 % (36/66) bolnikov.
Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to Baseline). 
Zmanjšanje inflamatornih lezij in preprečevanje poslabšanja abscesov in fistul z izcedkom so ocenili z rezultatom kliničnega odziva pri hidradenitis suppurativa (HiSCR - Hidradenitis Suppurativa Clinical Response; najmanj 50 % zmanjšanje skupnega števila abscesov in inflamatornih nodulov brez povečanja števila abscesov in fistul z izcedkom glede na izhodiščno število).
Psoriasis Study III (REACH) compared the efficacy and safety of Humira versus placebo in 72 patients with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. 
Študija pri psoriazi III (REACH) je primerjala učinkovitost in varnost zdravila Humira v primerjavi s placebom pri 72 bolnikih z zmerno do hudo kronično psoriazo v plakih in psoriazo na dlaneh in/ali stopalih.
• opportunistic infections (which include tuberculosis and other infections that occur when resistance to disease is lowered) 
• oportunistične okužbe (vključujejo tuberkulozo in druge okužbe, ki se pojavijo ob slabši telesni odpornosti na bolezen)
• autoimmune hepatitis (inflammation of the liver caused by the body's own immune system) 
• avtoimunski hepatitis (vnetje jeter, ki ga povzroči lastni imunski sistem)
No data are available on the secondary transmission of infection by live vaccines in patients receiving Humira. 
Podatkov o sekundarnem prenosu okužbe z živimi cepivi pri bolnikih, zdravljenih z zdravilomHumira, ni.
Humira is used to treat 
Zdravilo Humira se uporablja za zdravljenje
Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patients p = 0.015 c p = 0.031 
> 32 tednov 14 tednov a Odzivi »Ped ACR« 30/50/70 so bili 48. teden značilno večji kot pri bolnikih, ki so dobivali placebo b p = 0,015 c p = 0,031
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
Predpisovanje in izdaja zdravila je le na recept s posebnim režimom (Glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
• With one hand, gently grasp the cleaned areas of skin and hold firmly 
• Z eno roko obzirno primite očiščeni predel kože in ga trdno držite.
Among patients whose Humira treatment was withdrawn at Week 12 in Studies HS-I and HS-II, the HiSCR rate 12 weeks after re-introduction of Humira 40 mg weekly returned to levels similar to that observed before withdrawal (56.0 %). 
Med bolniki, pri katerih je bilo zdravljenje z zdravilom Humira ukinjeno v 12. tednu v študijah HS-I in HS-II, se je po ponovni uvedbi zdravila Humira 40 mg enkrat na teden raven kliničnega odziva (HiSCR) vrnila na podobno raven, kot so jo opazili pred ukinitvijo (56,0 %).
Week 2 
2. tednu.
A single Humira pre-filled syringe may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. 
Posamezna napolnjena injekcijska brizga zdravila Humira se lahko shranjuje pri temperaturi največ do 25 ºC za obdobje do 14 dni.
Melanoma and Merkel cell carcinoma have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8). 
Poročali so tudi o melanomu in karcinomu Merklovih celic pri bolnikih, zdravljenih z antagonisti TNF , vključno z adalimumabom (glejte poglavje 4.8).
fungal infections, 
glivične okužbe,
• mood swings (including depression) 
• spremenljivo razpoloženje (vključno z depresijo)
A total of 233 PASI 75 responders at Week 16 and Week 33 received continuous Humira therapy for 52 weeks in Psoriasis Study I, and continued Humira in the open-label extension trial. 
Skupno je 233 bolnikov, ki so imeli 16. in 33. teden odziv PASI 75, v študiji psoriaze I prejemalo stalno zdravljenje z zdravilom Humira 52 tednov ter so zdravljenje z zdravilom Humira nadaljevali v odprtem podaljšanem preskušanju.
Treatment with Humira may result in the formation of autoimmune antibodies. 
Zdravljenje z zdravilom Humira lahko povzroči nastanek avtoimunskih protiteles.
One pack contains 2 boxes, each containing 1 vial, 1 empty sterile syringe, 1 needle, 1 vial adapter and 2 alcohol pads. 
Eno pakiranje vsebuje 2 škatli, ena škatla pa vsebuje 1 vialo, prazno sterilno injekcijsko brizgo, 1 iglo, 1 adapter za vialo in 2 alkoholna zloženca.
In study UC-II, among those treated with Humira who were in remission at Week 8, 21/41 (51%) were in remission at Week 52. 
V študiji UC-II je bilo 21/41 bolnikov (51 %), ki so bili zdravljeni z zdravilom Humira in so dosegli remisijo 8. teden, v remisiji 52. teden.
• If you are allergic to adalimumab or any of the other ingredients of this medicine (listed in section 
• če ste alergični na adalimumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see Section 5.1) and to improve physical function. 
rentgenskim slikanjem je bilo dokazano, da zdravilo Humira upočasni hitrost napredovanja prizadetosti perifernih sklepov pri bolnikih s poliartikularno, simetrično podvrsto bolezni (glejte poglavje 5.1) in izboljša telesno funkcijo.
Table 28 Response, Remission and Mucosal Healing in Study UC-II (Percent of Patients) Placebo Humira 40 mg eow 
Preglednica 28 Odziv, remisija in celjenje sluznice v študiji UC-II (odstotek bolnikov) Placebo Humira 40 mg vsak drugi teden
Available data suggest that re-introduction of Humira after discontinuation for 70 days or longer resulted in the same magnitudes of clinical response and similar safety profile as before dose interruption. 
70 dni ali več, dosegla enako velik klinični odziv in je imela podobne varnostne značilnosti kot pred prekinitvijo.
• neuropathy (disorder of the nerves) 
• nevropatija (okvara živcev)
Humira is used to treat polyarticular juvenile idiopathic arthritis in patients from 2 years of age. 
Zdravilo Humira se uporablja za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa pri bolnikih od 2. leta starosti.
At Week 4 patients were randomised to 40 mg every other week, 40 mg every week, or placebo with a total study duration of 56 weeks. 
V 4. tednu so bili bolniki randomizirani na 40 mg vsak drugi teden, 40 mg vsak teden ali placebo celo trajanje študije 56 tednov.
In patients with moderately to severely active paediatric Crohn's disease, the rate of anti-adalimumab antibody development in patients receiving adalimumab was 3.3%. 
Delež pediatričnih bolnikov z zmerno do hudo aktivno Crohnovo boleznijo pri bolnikih, ki so prejeli adalimumab in razvili protitelesa proti adalimumabu je bil 3,3 %.
• a bump or open sore that doesn't heal; 
• bula ali odprta rana, ki se ne zaceli;
The safety and efficacy of multiple doses of Humira were assessed in adult patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of 2 to 3) in randomised, double-blind, placebo-controlled studies. 
Varnost in učinkovitost večkratnih odmerkov zdravila Humira so ocenili pri odraslih z zmernim do hudo aktivnim ulceroznim kolitisom (ocena Mayo od 6 do 12 z endoskopsko podoceno 2 do 3) v randomiziranih, dvojno slepih, s placebom kontroliranih študijah.
Your doctor will decide if Humira should be used with methotrexate or alone. 
Vaš zdravnik se bo odločil, ali naj se zdravilo Humira uporablja z metotreksatom ali samo.
• Vaccinations: if possible children should be up to date with all vaccinations before using Humira. 
• Cepljenja: če je mogoče, naj vaš otrok pred začetkom uporabe zdravila Humira opravi vsa potrebna cepljenja.
Humira is recommended for use in combination with methotrexate. 
Priporočljiva je uporaba zdravila Humira v kombinaciji z metotreksatom.
Children and adolescents from 6 to 17 years of age weighing 40 kg or more The usual dose regimen is 80 mg (as two 40 mg injections in one day) initially followed by 40 mg two weeks later. 
Otroci in mladostniki, stari od 6 do 17 let, ki tehtajo 40 kg ali več Običajni začetni odmerek je 80 mg (dve 40 mg injekciji v enem dnevu), ki mu sledi 40 mg dva tedna kasneje.
Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients continued on Humira 40 mg every other week for 10 years. 
Od 542 bolnikov, ki so bili randomizirani na zdravilo Humira 40 mg vsak drugi teden, jih je 170 nadaljevalo zdravljenje z zdravilom Humira 40 mg vsak drugi teden še 10 let.
In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment. 
V študijah revmatoidnega artritisa I-IV so z zdravilom Humira zdravljeni bolniki v primerjavi s prejemniki placeba dosegli statistično značilen odziv 20 in 50 po ACR že en do dva tedna po začetku zdravljenja.
 PASI 75 
PASI 75 in
• moderate to severe hidradenitis suppurativa in adults and 
• zmernega do hudega hidradenitis suppurativa pri odraslih in
All p-values are pairwise comparisons of proportions for Humira versus placebo p < 0.001 p < 0.01 
Vse p-vrednosti so parne primerjave razmerja zdravila Humira proti placebu * p < 0,001 ** p < 0,01
With your free hand, gently grasp a sizable area of the cleaned skin at the injection site and hold firmly (see below). 
S prosto roko obzirno primite očiščeni predel kože in ga trdno držite (glejte spodaj).
Patients were randomised to 40 mg of Humira or placebo every other week for 24 weeks. 
Bolnike so randomizirali na 40 mg zdravila Humira ali placebo vsak drugi teden za 24 tednov.
• serious infections (including blood poisoning and influenza) 
• resne okužbe (vključno z zastrupitvijo krvi in gripo)
In a study of 64 patients with rheumatoid arthritis that were treated with Humira, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils. 
V študiji 64 bolnikov z revmatoidnim artritisom, zdravljenih z zdravilom Humira, niso odkrili znakov zavrtja odložene preobčutljivosti, znižanja koncentracije imunoglobulinov ali spremembe števila efektorskih celic T in B, naravnih celic ubijalk, monocitov/makrofagov ali nevtrofilcev.
• Non-infectious uveitis 
• neinfekcijskega uveitisa
You will then hear a loud ‘click' as the needle is released and you will feel a small prick as the needle advances. 
Ko se bo igla sprožila, boste zaslišali glasen "klik", in ob njenem vbodu boste začutili droben bodljaj.
In patients with Crohn's disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and in 19/487 subjects (3.9%) with ulcerative colitis. 
Pri bolnikih s Crohnovo boleznijo so identificirali protitelesa proti adalimumabu pri 7 od 269 bolnikov (2,6 %) in pri 19 od 487 bolnikov (3,9 %) z ulceroznim kolitisom.
A greater proportion of patients on Humira had no disease flare during the double-blind period, when compared with those on placebo (70.4% vs. 47.1%, p<0.001) (Figure 1). 
Pri večjem deležu bolnikov, ki so prejemali zdravilo Humira, v dvojno slepem obdobju ni prišlo do ponovnega zagona bolezni v primerjavi s tistimi, ki so prejemali placebo (70,4 % v primerjavi s 47,1 %, p < 0,001) (slika 1).
The Humira pre-filled syringe is available in a pack containing 2 pre-filled syringes with 2 alcohol pads. 
Napolnjena injekcijska brizga zdravila Humira je na voljo v pakiranju, ki vsebuje 2 napolnjeni injekcijski brizgi z 2 alkoholnima zložencema.
Patients were then re-treated with adalimumab 0.8 mg/kg eow for an additional 16 weeks and response rates observed during retreatment were similar to the previous double-blind period: PASI 75 response of 78.9% (15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects). 
Bolniki so bili nato znova zdravljeni z adalimumabom v odmerku 0,8 mg/kg vsak drugi teden še nadaljnjih 16 tednov, pri čemer so bile opažene stopnje odziva podobne kot v prejšnjem dvojno slepem obdobju: odziv PASI 75 pri 78,9 % (15 od 19 oseb) in PGA čisto ali minimalno pri 52,6 % (10 od 19 oseb).
The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active Crohn's disease (Crohn's Disease Activity Index (CDAI)  220 and  450) in randomised, double-blind, placebo-controlled studies. 
Varnost in učinkovitost zdravila Humira so ovrednostili pri preko 1500 bolnikih z zmerno do hudo aktivno Crohnovo boleznijo (Crohn's Disease Activity Index (CDAI) ≥ 220 in ≤ 450) v randomizirani, dvojno slepi, s placebom kontrolirani študiji.
• heart problems that can cause shortness of breath or ankle swelling 
• težave s srcem, ki lahko povzročijo kratko sapo ali otekanje gležnjev
DO NOT use if the liquid is cloudy, discoloured or has flakes or particles in it. 
Zdravila NE UPORABLJAJTE, če je tekočina motna, obarvana ali vsebuje kosmiče ali delce.
Each new injection should be given at least 3 cm from the last injection site. 
Vsako naslednjo injekcijo morate dati vsaj 3 cm od mesta prejšnje injekcije.
Humira is injected under the skin (subcutaneous use). 
Zdravilo Humira se injicira pod kožo (subkutana uporaba).
Similar remission rates were observed for the 160/80 mg and 80/40 mg induction regimens by Week 8 and adverse events were more frequently noted in the 160/80 mg group. 
Podobne stopnje remisije so opazili za 160/80 mg in 80/40 mg indukcijski režim v 8. tednu.
RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were  18 years old, had failed therapy with at least one disease-modifying, anti rheumatic drug and had insufficient efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant) every week and whose methotrexate dose remained constant at 10 to 25 mg every week. 
V študiji revmatoidnega artritisa I je bilo ocenjeno 271 bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let, pri katerih zdravljenje z vsaj enim imunomodulirajočim antirevmatičnim zdravilom ni bilo uspešno, pri katerih metotreksat v odmerkih od 12,5 do 25 mg (10 mg, če so bili intolerantni za metotreksat) vsak teden ni bil dovolj učinkovit in pri katerih je odmerek metotreksata od 10 do 25 mg ostal stalen vsak teden.
You should not take Humira with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection. 
Zdravila Humira ne smete jemati z zdravili, ki vsebujejo učinkovini anakinro ali abatacept zaradi povečanega tveganja za resne okužbe.
Improvement in number of active joints with arthritis was maintained during the OL period through Week 156 for the 26 of 31 (84%) patients in the Humira group who remained in the study. 
Izboljšanje v številu aktivnih sklepov z artritisom se je ohranilo v obdobju odprtega preskušanja po 156. tednu pri 26 od 31 (84 %) bolnikov, ki so ostali v študiji in ki so prejemali zdravilo Humira.
• Ankylosing spondylitis, 
• ankilozirajoči spondilitis,
The symptoms described above can be signs of the below listed side effects, which have been observed with Humira. 
Opisani simptomi so lahko znaki naslednjih neželenih učinkov, ugotovljenih med uporabo zdravila
Among patients who were at least partial responders at Week 12, and who received continuous weekly Humira therapy, the HiSCR rate at Week 48 was 68.3% and at Week 96 was 65.1%. 
Pri bolnikih z vsaj delnim odzivom na zdravilo Humira v odmerku 40 mg v 12. tednu, in ki so prejemali neprekinjeno tedensko terapijo Humira vsak teden, je bila stopnja kliničnega odziva (HiSCR) v 48. tednu 68,3 % in v 96. tednu 65,1 %.
In adult patients with Crohn's disease, anti-adalimumab antibodies were identified in 7/269 subjects 
Pri bolnikih s Crohnovo boleznijo so identificirali protitelesa proti adalimumabu pri 7 od 269 bolnikov
After 12 weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1 of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or placebo from Week 12 to Week 35). 
Po 12 tednih terapije so bolnike, ki so prejemali zdravilo Humira v obdobju A, ponovno randomizirali v obdobju B v eno izmed treh skupin zdravljenja (zdravilo Humira 40 mg vsak teden, zdravilo Humira 40 mg vsak drugi teden ali placebo od 12. do 35. tedna).